NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Cristiano Ferlini
AstraZeneca, Sweden - Södertälje / Sweden
Others
AD Scientific Index ID: 4399875
-
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Cristiano Ferlini's MOST POPULAR ARTICLES
1-)
Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patientsS Mozzetti, C Ferlini, P Concolino, F Filippetti, G Raspaglio, S Prislei, ...Clinical Cancer Research 11 (1), 298-305, 20054582005
2-)
Role of microRNAs in drug-resistant ovarian cancer cellsA Sorrentino, CG Liu, A Addario, C Peschle, G Scambia, C FerliniGynecologic oncology 111 (3), 478-486, 20084402008
3-)
Defining “mutation” and “polymorphism” in the era of personal genomicsR Karki, D Pandya, RC Elston, C FerliniBMC medical genomics 8, 1-7, 20152992015
4-)
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trialM Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ...Journal of Clinical Oncology 39 (18), 1959-1970, 20213282021
5-)
Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patientsG Ferrandina, GF Zannoni, E Martinelli, A Paglia, V Gallotta, S Mozzetti, ...Clinical cancer research 12 (9), 2774-2779, 20063092006
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept